baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Финансовые показатели

Новости

TraderScreen

HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /

15.11.2024 8:16:07	Изменение -0.080	Объем сделки	Бид18:52:36	Предложение18:52:36	Рыночная капитализация	Дивидендная доходность	Коэффициент Цена/Доход
2.270EUR	-3.40%	0 Оборот: 0.000	-Величина цены спроса: -	-Величина цены предложения: -	77.92 млнEUR	0.00%	-

GlobeNewswire 26.05.2021 Immatics Announces Changes to its Board of Directors

GlobeNewswire 11.03.2020 RedHill Biopharma Provides Update on Opaganib (Yeliva®)

GlobeNewswire 19.10.2018 ADC Contract Manufacturing Market, 2030

GlobeNewswire 17.07.2018 APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

GlobeNewswire 16.11.2017 Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%

GlobeNewswire 24.08.2017 Global Cell Line Development Services Market, 2027

GlobeNewswire 06.07.2017 Biopharmaceutical Contract Manufacturing Market, 2027

GlobeNewswire 12.11.2007 HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE

GlobeNewswire 21.05.2007 Clinical effectiveness and tolerability of Fosalvudine (HIV) confirmed

GlobeNewswire 17.05.2007 Fosfluridine Tidoxil shows effectiveness in Actinic Keratosis

GlobeNewswire 05.02.2007 Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis

GlobeNewswire 10.01.2007 Heidelberg Pharma becomes a Corporation

GlobeNewswire 09.10.2006 Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients

GlobeNewswire 02.10.2006 Heidelberg Pharma raises 16 million EUR (20 million USD) in series B-Round

HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /

Если вы хотите получить ответ на свой отзыв, укажите, пожалуйста, адрес своей электронной почты.